Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRAKLE: RD03/2016 for Bacterial Conjunctivitis
NCT06616922Phase 2Completed
- Sponsor
- NTC Pharma
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial of NTC014 in bacterial conjunctivitis (BC) (2 arms), sponsored by NTC Pharma. Primary endpoint: Proportion of patients with microbiological eradication. Started Nov 2021; status: completed.
02
Drugs
NTC014
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT06616922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616922.